Georgia's Online Cancer Information Center

Sarcoma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Sarcoma
Cancer Type = Sarcoma
There are currently 34 active Sarcoma clinical trials in Georgia.
1.
9-ING-41 in Patients With Advanced Cancers
Cancer Type
Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT03678883
Protocol IDs
1801
NCI-2018-03166
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT04994132
Protocol IDs
ARST2031
ARST2031
NCI-2021-06711
3.
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Cancer Type
Sarcoma
NCT ID
NCT04554914
Protocol IDs
ATA129-EBV-205
NCI-2020-07698
2020-000177-25
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Neuroblastoma, Sarcoma
NCT ID
NCT02644460
Protocol IDs
AFLACST1501
NCI-2015-02256
IRB00083793
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
5.
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Cancer Type
Bile Duct Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Neuroendocrine Tumor, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT02568267
Protocol IDs
RXDX-101-02
NCI-2015-01848
Treatment Sites (2)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
Cancer Type
Sarcoma
NCT ID
NCT03206450
Protocol IDs
ALTE16C1
ALTE16C1
COG-ALTE16C1
NCI-2017-01152
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
7.
NCORP Trial
Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT02567435
Protocol IDs
ARST1431
NCI-2015-01644
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
8.
Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Wilms Tumor
NCT ID
NCT03213652
Protocol IDs
APEC1621F
APEC1621F
NCI-2017-01243
APEC1621F
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
9.
Erdafitinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with FGFR Mutations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03210714
Protocol IDs
APEC1621B
NCI-2017-01159
APEC1621B
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
10.
Informational Meetings for Planning and Coordinating Treatment, The IMPACT Trial
Cancer Type
Brain & Spinal Cord Tumor, Sarcoma, Solid Tumor
NCT ID
NCT04330833
Protocol IDs
IUSCC-0705
NCI-2021-01462
11.
Ivosidenib in Treating Patients with Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with IDH1 Mutations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT04195555
Protocol IDs
APEC1621K
APEC1621K
NCI-2019-08098
12.
Larotrectinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with NTRK Fusions (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03213704
Protocol IDs
APEC1621A
APEC1621A
NCI-2017-01264
APEC1621A
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
13.
Losartan and Sunitinib for the Treatment of Relapsed or Refractory Osteosarcoma
Cancer Type
Sarcoma
NCT ID
NCT03900793
Protocol IDs
18-2740
NCI-2019-06119
18-2740.cc
14.
Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Cancer Type
Lung Cancer, Sarcoma, Solid Tumor, Unknown Primary
NCT ID
NCT04526509
Protocol IDs
209012
NCI-2020-11491
15.
MDM2 Inhibitor AMG-232 (KRT-232) and Radiation Therapy in Treating Patients with Soft Tissue Sarcoma
Cancer Type
Sarcoma
NCT ID
NCT03217266
Protocol IDs
NRG-DT001
NRG-DT001
NCI-2017-01234
Treatment Sites (1)
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
17.
Nelfinavir Mesylate in Treating Patients with Kaposi Sarcoma
Cancer Type
Sarcoma
NCT ID
NCT03077451
Protocol IDs
AMC-098
AMC-098
NCI-2016-00071
AMC 098
AMC-098
098
Treatment Sites (3)
18.
NCORP Trial
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (10)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
Olaparib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03233204
Protocol IDs
APEC1621H
APEC1621H
NCI-2017-00766
APEC1621H
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
20.
Palbociclib in Treating Patients with Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma
NCT ID
NCT03526250
Protocol IDs
APEC1621I
NCI-2018-00863
APEC1621I
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
21.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type
Colon/Rectal Cancer, Pancreatic Cancer, Sarcoma, Solid Tumor
NCT ID
NCT03715933
Protocol IDs
Ph1 INBRX-109
NCI-2018-03556
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
REtroperitoneal SArcoma Registry: an International Prospective Initiative
Cancer Type
Sarcoma
NCT ID
NCT03838718
Protocol IDs
201/16
NCI-2019-08030
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
23.
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Cancer Type
Lymphoma, Neuroblastoma, Sarcoma
NCT ID
NCT03458728
Protocol IDs
19176
NCI-2018-00809
2017-000383-15
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
24.
Samotolisib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03213678
Protocol IDs
APEC1621D
APEC1621D
NCI-2017-01249
APEC1621D
Treatment Sites (1)
25.
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders with Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT04320888
Protocol IDs
APEC1621N
APEC1621N
NCI-2020-01756
Treatment Sites (1)
26.
Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Cancer Type
Sarcoma, Solid Tumor
NCT ID
NCT04469530
Protocol IDs
AFLACST1903
STUDY00000113
NCI-2020-01654
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Cancer Type
Neuroblastoma, Sarcoma
NCT ID
NCT03709680
Protocol IDs
A5481092
NCI-2019-02215
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
28.
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Neuroendocrine Tumor, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04579757
Protocol IDs
2020-012-GLOB1
NCI-2021-01887
29.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
Treatment Sites (1)
30.
Testing Atezolizumab and Bevacizumab in People with Advanced Alveolar Soft Part Sarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT03141684
Protocol IDs
10005
NCI-2016-01040
17-C-007
CC 17-C-0074
17-C-0074
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
31.
Testing Atezolizumab in Patients >= 2 Years Old with Newly Diagnosed, Unresectable, or Metastatic Clear Cell Sarcoma or Chondrosarcoma
Cancer Type
Sarcoma
NCT ID
NCT04458922
Protocol IDs
10398
10398
NCI-2020-04634
000081
20-C-XXXX
32.
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Cancer Type
Brain & Spinal Cord Tumor, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Thyroid Cancer
NCT ID
NCT04284774
Protocol IDs
APEC1621M
APEC1621M
NCI-2020-01015
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
33.
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Cancer Type
Sarcoma
NCT ID
NCT04616560
Protocol IDs
PEPN1924
PEPN1924
NCI-2020-08428
34.
Vemurafenib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Germ Cell Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03220035
Protocol IDs
APEC1621G
APEC1621G
NCI-2017-01244
APEC1621G
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.